First Biomarker Discovered that Predicts Prostate Cancer Outcome

**Mayo Clinic researchers have identified the first immune molecule that appears to play a role in prostate cancer development and in predicting cancer recurrence and progression after surgery. The report on the B7-H3 molecule by Mayo Clinic Cancer Center appears today in Cancer Research.** "This discovery will allow physicians to individualize treatment and observation plans for prostate cancer patients," says Timothy Roth, M.D., a Mayo Clinic urology resident and lead author of the study. "Being able to tell a patient his specific risk after surgery, and perhaps even prior to surgery, will be a huge step forward." Until now there were no strongly-predictive molecules for **prostate cancer**. The most notable other prostate biomarkers, prostate-specific antigen (PSA), and prostate-specific membrane antigen (PSMA) are useful to diagnose prostate cancer. However, PSA tends to leave prostate cancer cells and migrate throughout the body, making it a poor target for therapy.... Whole article on "Bio":[ http://www.bio.com/newsfeatures/newsfeatures_research.jhtml;jsessionid=L2RQKMJ4VVDTHR3FQLMCFEWHUWBNSIV0?cid=32900001]

---